



Alliance for Biomedical Research in Europe

**'THE FUTURE OF HEALTH RESEARCH AND INNOVATION IN
EUROPE: THE NEED FOR STRATEGIC ACTION'**

- WELCOME ADDRESS -

BELGIAN ROYAL ACADEMY OF MEDICINE, BRUSSELS · 23 MAY 2012

ORGANISED JOINTLY BY

ALLIANCE FOR BIOMEDICAL RESEARCH IN EUROPE AND EUROPEAN COMMISSION



Alliance for Biomedical Research in Europe

Who is the BioMed Alliance?

-Speaking with one voice for the first time –

- 20 major European medical and biomedical scientific societies, across all disciplines
- 250,000 biomedical researchers from across Europe
- To take all actions necessary:
 - ✓ To promote excellence in biomedical research
 - ✓ To ensure appropriate support and thereby
 - ✓ Improve the well-being of all citizens in Europe



Alliance for Biomedical Research in Europe

OUR MEMBERSHIP



EUROPEAN
CANCER
ORGANISATION



EUROPEAN
SOCIETY OF
CARDIOLOGY®



ERS

EUROPEAN
RESPIRATORY
SOCIETY



eular



ESR
European Society of Radiology



EASL
EUROPEAN
ASSOCIATION
FOR THE STUDY
OF THE LIVER

EANM
European Association of Nuclear Medicine

ESCMID
EUROPEAN SOCIETY
OF CLINICAL MICROBIOLOGY
AND INFECTIOUS DISEASES

UNITED EUROPEAN
GASTROENTEROLOGY
ueg

eshre
SCIENCE MOVING
PEOPLE
MOVING SCIENCE

EFIS
European Federation of
Immunological Societies



EUROPEAN
HEMATOLOGY
ASSOCIATION



Alliance for Biomedical Research in Europe

Led by a cross-disciplinary, expert Executive Committee

- ***Ulf Smith, President, EASD***
- ***Julio Celis, Vice-President, ECCO***
- ***Karin Sipido, Vice-President, ESC***
- ***Laurent Nicod, Treasurer, ERS***



Alliance for Biomedical Research in Europe

Consultation with eminent Core Group members

Multidisciplinary: professionals, policymakers, patient advocates and pharmaceutical industry

■ Sir George Alberti

■ Maciej Banach

■ Peter J Barnes

■ Laurent Degos

■ Wilfried Ellmeier

■ Valentin Fuster

■ Silke Mader

■ Michael Manns

■ Luis Marti-Bonmati

■ Martine Piccart

■ Tomas Zima

Advisors:

■ Richard Bergstrom

■ José Mariano Gago

■ Harald zur Hausen

■ Liselotte Højgaard

■ Stella Kyriakidis

■ Peter Lange



Alliance for Biomedical Research in Europe

Why such an Alliance? *Call to action!*

- An ageing population
- Growing prevalence of chronic diseases
- A declining labour force
- Rising healthcare costs





Alliance for Biomedical Research in Europe

The NCD Cost Tally


- **Cancer:** US\$ 290 billion in 2010 rising to US\$ 458 billion in 2030
- **Cardiovascular disease:** US\$ 863 billion in 2010 rising to US\$ 1.04 trillion in 2030
- **COPD:** US\$ 2.1 trillion in 2010 US\$ rising to US\$ 4.8 trillion in 2030
- **Diabetes:** US\$ 500 billion in 2010 rising to at least US\$ 745 billion in 2030
- **Mental illness:** US\$ 2.5 trillion in 2010 rising to US\$ 6.0 trillion by 2030



Alliance for Biomedical Research in Europe

**“IF YOU THINK RESEARCH IS EXPENSIVE, TRY
DISEASE”**

Mary Lasker, 1901–94





Alliance for Biomedical Research in Europe

Health is Wealth

In a time of economic gloom:

These challenges can only be met by increased **knowledge through biomedical research** and a **coherent and strategic European action** that engages all key stakeholders in healthcare



Alliance for Biomedical Research in Europe

Major Return on Investment

“... the total health and GDP gains to public/charitable CVD research in the UK 1975–1992 give a total Initial Rates of Return (IRR) of around 39%. In other words, a £1.00 investment in public CVD research produced a stream of benefits that is equivalent in value to earning £0.39 per year in perpetuity”.

“Medical Research: What’s it worth? ” - UK Medical Research Council Report 2008



Alliance for Biomedical Research in Europe

Biomedical research

**Is an outstanding example of research-driven innovation which,
through**

- ✓ *health promotion and prevention (including research)***
- ✓ *development of diagnostic and medicinal products***
- ✓ *improvement of medical treatments, and advances in health services research***

**may boost scientific excellence and knowledge as drivers of
future growth in the European Research Area (ERA)**



Alliance for Biomedical Research in Europe

Call for Action:

- Boost biomedical and clinical research with appropriate funding
- **Create a strategic action for health in the form of a scientific-led European Council for Health Research**
- Encourage cross-talk and best practices across disciplines and accelerate research-driven innovation
- Implement structured consultation with **all relevant stakeholders** to steer health research and ensure proper targeting and priority-setting for funding
- Encourage long-term strategic research programmes capable of triggering global multidisciplinary partnerships



Alliance for Biomedical Research in Europe

Activities to Date

- www.biomedeuropa.org
- Statutes
- BioMed Alliance response to Green Paper
- Position Paper, 'Horizon 2020: Addressing the Health Challenge', Nov. 2012
- Article, European Voice, Dec. 2011
- High-level Meeting at European Parliament, Jan. 2012
- 2 Press Releases
- **Creation of Core Group and meeting to establish roadmap**
- **European Council for Health Research Concept Paper**, consensus by all members
- European Parliament amendments
- Policymaker contact programme
- Concept Paper, Dissemination campaign



Alliance for Biomedical Research in Europe

SESSION ONE: AIMS TO SET THE SCENE – HEALTH IS WEALTH

**“Achieving a Healthier Europe Through Research
& Innovation: Defining the Needs”**

SESSION TWO: PARTNERSHIP TO ACCELERATE INNOVATION

**“Health Research & Innovation in Europe:
Coordination as a Success Factor”**



Alliance for Biomedical Research in Europe

SESSION THREE: H2020 - A WINDOW OF OPPORTUNITY

**“The Future of R&I in Europe: the Need for a
Strategic Action”**

SESSION FOUR:

**The Future of R&I in Europe: the Need for a
Strategic Action – Views from Stakeholders**